AbbVie (NYSE: ABBV) EVP granted performance stock awards and options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
AbbVie executive Nicholas Donoghoe reported multiple equity awards tied to performance goals. On February 18, 2026, he acquired an option to buy 20,312 AbbVie shares, vesting in three equal annual installments starting on February 18, 2027.
He also received performance-based stock awards of 13,031, 4,632, 5,172 and 6,222 AbbVie shares. These stock units vested after AbbVie’s Compensation Committee certified achievements in earnings per share, relative total shareholder return and relative return on equity, with shares scheduled to be issued on February 28, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Donoghoe Nicholas
Role
EVP, CHIEF BUS/STRAT OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option (Right to buy) | 20,312 | $0.00 | -- |
| Grant/Award | Common Stock, $0.01 par value | 13,031 | $0.00 | -- |
| Grant/Award | Common Stock, $0.01 par value | 4,632 | $0.00 | -- |
| Grant/Award | Common Stock, $0.01 par value | 5,172 | $0.00 | -- |
| Grant/Award | Common Stock, $0.01 par value | 6,222 | $0.00 | -- |
Holdings After Transaction:
Option (Right to buy) — 20,312 shares (Direct);
Common Stock, $0.01 par value — 71,278 shares (Direct)
Footnotes (1)
- Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,771 on February 18, 2027, 6,771 on February 18, 2028, and 6,770 on February 18, 2029.
FAQ
What did AbbVie (ABBV) EVP Nicholas Donoghoe report in this Form 4?
Nicholas Donoghoe reported multiple equity awards from AbbVie, including a stock option for 20,312 shares and several performance-based stock awards. These were granted or vested after AbbVie’s Compensation Committee certified achievement of specific earnings and return metrics.
What performance measures affect the AbbVie stock awards to Nicholas Donoghoe?
The stock awards are tied to multiple performance measures, including earnings per share, relative total shareholder return and a relative return on equity metric. Vesting occurred after AbbVie’s Compensation Committee certified achievement of these goals, with share delivery scheduled for February 28, 2026.
When will the vested AbbVie performance stock awards be issued to Nicholas Donoghoe?
The filing states that vested performance-based stock and restricted stock unit awards will be issued on February 28, 2026. Although performance conditions were certified earlier, the actual delivery of AbbVie common shares occurs on that specified future issuance date.
What is the vesting schedule for Nicholas Donoghoe’s AbbVie stock option grant?
The option vests in three annual tranches: 6,771 shares on February 18, 2027, another 6,771 shares on February 18, 2028, and 6,770 shares on February 18, 2029. This staggered schedule gradually makes the entire 20,312-share option exercisable over time.
Are Nicholas Donoghoe’s AbbVie equity awards direct holdings?
Yes. The transactions are reported as directly owned, indicated by the ownership code "D" and direct_or_indirect classification "D". This means the AbbVie common stock and option awards listed are held directly by Nicholas Donoghoe, rather than through an intermediary entity.